Oric Pharmaceuticals (ORIC) Long-Term Deferred Tax (2019 - 2025)

Oric Pharmaceuticals (ORIC) posted Long-Term Deferred Tax of $2.1 million for Q4 2025, down 12.47% on a QoQ basis from $2.4 million in Q1 2020.

Oric Pharmaceuticals (ORIC) Long-Term Deferred Tax (2019 - 2025) Analysis & Trends

Oric Pharmaceuticals' Long-Term Deferred Tax history runs 3 years deep, the most recent figure standing at $2.1 million for Q4 2025.

Quarterly Long-Term Deferred Tax changed N/A year-over-year to $2.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.1 million (changed N/A YoY) and the FY2025 annual result came in at $2.1 million, changed N/A from the prior year.
Long-Term Deferred Tax was $2.1 million for Q4 2025 at Oric Pharmaceuticals, down from $2.4 million in the prior quarter.
Across five years, Long-Term Deferred Tax topped out at $2.1 million in Q4 2025 and bottomed at $2.1 million in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Oric Pharmaceuticals	1.15 Bn	866.67 Mn	-

Download Data